Related Experiment Videos
Cardiac allograft vasculopathy
1Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA.
Insights
Cardiac allograft vasculopathy (CAV) is a major concern after heart transplants, driven by immune and non-immune factors. Early detection and prevention are key to improving long-term transplant function and patient outcomes.
Area of Science:
- Cardiology
- Transplantation Immunology
- Vascular Biology
Background:
- Cardiac transplantation is a vital treatment for end-stage heart disease.
- Cardiac allograft vasculopathy (CAV) significantly impacts long-term transplanted heart function.
- CAV involves complex immunologic and non-immunologic factors leading to vascular injury and inflammation.
Purpose of the Study:
- To highlight the significance of Cardiac Allograft Vasculopathy (CAV) in heart transplant recipients.
- To discuss the contributing factors and early features of CAV.
- To emphasize the importance of early detection and prevention strategies for CAV.
Main Methods:
- Review of existing literature on Cardiac Allograft Vasculopathy (CAV).
- Discussion of diagnostic tools including coronary angiography and intravascular ultrasound.
- Analysis of contributing factors such as dyslipidemia, oxidant stress, immunosuppressants, and viral infections.
Main Results:
- Endothelial dysfunction is an early indicator of CAV.
- Intravascular ultrasound reveals negative vascular remodeling contributes to luminal narrowing in CAV.
- CAV is characterized by accelerated, diffuse obliterative coronary arteriosclerosis.
Conclusions:
- Early identification of CAV is crucial for improving long-term prognosis after heart transplantation.
- Prevention of CAV progression is a primary therapeutic objective.
- Current revascularization procedures have limited efficacy due to the diffuse nature of CAV.
Abstract:
Cardiac transplantation has emerged as a valuable therapy for various end-stage cardiac disorders. Cardiac allograft vasculopathy (CAV), an unusually accelerated and diffuse form of obliterative coronary arteriosclerosis, determines long-term function of the transplanted heart. Cardiac allograft vasculopathy is a complicated interplay between immunologic and nonimmunologic factors resulting in repetitive vascular injury and a localized sustained inflammatory response. Dyslipidemia, oxidant stress, immunosuppressive drugs, and viral infection appear to be important contributors to disease development. Endothelial dysfunction is an early feature of CAV and progresses over time after transplantation. Early identification of CAV is essential if long-term prognosis is to be improved. Annual coronary angiography is performed for diagnostic and surveillance purposes. Intravascular ultrasound is a more sensitive diagnostic tool for early disease stages and has revealed that progressive luminal narrowing in CAV is in part due to negative vascular remodeling. Because of the diffuse nature of CAV, percutaneous and surgical revascularization procedures have a limited role. Prevention of CAV progression is a primary therapeutic goal.